Inhibition of KDEL receptors enhances immune response in tumors, suggesting new strategies for immunotherapy.
Key Points
Complete tumor regression occurs through enhanced infiltration of immune cells, particularly macrophages and neutrophils, following KDEL receptor inhibition.
Inhibition of KDELR2 shows significant activation of the innate immune response, leading to regression of both immunogenic and non-immunogenic tumors.
Intratumoral delivery of siDKELR2 via lipid nanoparticles successfully induces changes in the tumor microenvironment, promoting tumor regression.
The findings highlight a novel therapeutic approach to overcome resistance in 'cold' tumors and improve overall immunotherapy efficacy.